 Proactive Investors USA & Canada |
AstraZeneca, Dynavax amend agreement to accelerate development of asthma drug
Proactive Investors USA & Canada AstraZeneca (NYSE:AZN) and Dynavax Technologies (NASDAQ:DVAX) announced Wednesday they have amended their collaboration agreement so as to accelerate the development of AZD1419, intended for the treatment of asthma. Under the terms of the agreement, … Dynavax and AstraZeneca to Advance TLR-9 Agonist Into Clinic for Asthma Dynavax gets $3M in reworked asthma deal with AstraZeneca |
View full post on asthma – Google News